NW-8-461
/ Lupeng Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Preclinical evaluation of a novel orally bioavailable MDM2 PROTAC, NW-8-461, in acute leukemia and myelofibrosis
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Preclinical • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology
1 to 1
Of
1
Go to page
1